Jump to main content
Jump to site search

Issue 69, 2018
Previous Article Next Article

Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Author affiliations

Abstract

Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2′-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.

Graphical abstract: Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

Back to tab navigation

Supplementary files

Publication details

The article was received on 18 Jun 2018, accepted on 03 Aug 2018 and first published on 03 Aug 2018


Article type: Communication
DOI: 10.1039/C8CC04860F
Citation: Chem. Commun., 2018,54, 9655-9658
  •   Request permissions

    Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines

    J. Wu, W. Li, P. Chen, B. Zhang, H. Hu, Q. Li, L. Zhao, Y. Chen, Y. Zhao and Y. Li, Chem. Commun., 2018, 54, 9655
    DOI: 10.1039/C8CC04860F

Search articles by author

Spotlight

Advertisements